[Technological evolutions in blood donation screening and their impact on the residual risk].
Authors: Barlet V,
Address: Laboratoires QBD, site de Metz-Tessy, Établissement français du sang Rhône-Alpes, route de Pringy, 74370 Metz-Tessy, France. email@example.com
Journal: Transfus Clin Biol.
Publication: 2011 Apr;18(2):292-301. doi: 10.1016/j.tracli.2011.02.025. Epub 2011 Apr 3.
During the two last decades, the risk of viral transfusion transmission for some infectious agents (HIV, HCV, HBV and HTLV) has been markedly reduced by improved donor screening, improvements of serological assays and the implementation of minipool nucleic acid testing for HIV-1 and HCV viruses. However, implementation during the year 2010 of nucleic acid testing for the detection of HIV RNA, HCV RNA and HBV DNA in a single triplex assay may provide additional safety, especially after acute infection during the window period. New Procleix(®) Tigris(®) technology (Novartis) allow the French blood screening laboratories to answer their actual requirements in terms of security and throughput and to implement nucleic acid testing in case of emergent risks requiring a direct detection of viruses. Furthermore, Tigris(®) is a fully automated system with high level of security during the analytical process, reducing the number of invalid or non-available results observed with the previous semi-automated technologies. Moreover, renewal of material by fully automated and secure systems, especially for the critical step of sample pipeting, may provide additional safety in blood screening laboratories.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.
The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.